<SEC-DOCUMENT>0001615774-17-003684.txt : 20170718
<SEC-HEADER>0001615774-17-003684.hdr.sgml : 20170718
<ACCEPTANCE-DATETIME>20170718081100
ACCESSION NUMBER:		0001615774-17-003684
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170718
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170718
DATE AS OF CHANGE:		20170718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		17968533

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s106841_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C.&nbsp;20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of report (Date of earliest event reported):
July 18, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>NEKTAR THERAPEUTICS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact Name of Registrant as Specified in
Charter)</B></P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 34%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>0-24006</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3134940</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0 0; text-align: center"><B>(State or Other Jurisdiction</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0 0; text-align: center"><B>of Incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0 0; text-align: center"><B>(Commission</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0 0; text-align: center"><B>File Number)</B></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>455 Mission Bay Boulevard South</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>San Francisco, California 94158</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of Principal Executive Offices
and Zip Code)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number,
including area code: (415) 482-5300</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/0.05pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT>&nbsp;<FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.</FONT>&nbsp;<FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/0.05pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Item 7.01.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation
FD Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 18, 2017, Nektar
Therapeutics, a Delaware corporation (&ldquo;Nektar&rdquo;), issued a press release (the &ldquo;Press Release&rdquo;) announcing
topline data from an oral Human Abuse Potential (HAP) study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain.
A copy of the Press Release reporting results from the HAP study is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the Press Release, Nektar
announced that it would hold a Webcast conference call on July 18, 2017 at 5:45 a.m. (Pacific Time)/8:45 a.m. (Eastern Time) to
review the results from the HAP study. This conference call is accessible through a link that is posted on the home page and Investor
section of the Nektar website: http://www.nektar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13pt">The information in this
report, including the exhibit hereto, is being furnished and shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not
be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Item
9.01.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%; border-bottom: black 1pt solid"><B>Exhibit</B><BR>
<B>Number</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 92%; border-bottom: black 1pt solid"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release titled &ldquo;Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain&rdquo; issued by Nektar Therapeutics on July 18, 2017. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%">
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/0.05pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; padding-right: 0.8pt; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirement of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%"><B>NEKTAR THERAPEUTICS</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>July 18, 2017</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid"><I>/s/ Mark A. Wilson</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Mark A. Wilson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>General Counsel and Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%">
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: black 1pt solid; text-align: center"><B>Exhibit</B><BR>
<B>No.</B></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 91%; border-bottom: black 1pt solid"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release titled &ldquo;Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain&rdquo; issued by Nektar Therapeutics on July 18, 2017. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%">
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s106841_ex99-1.htm
<DESCRIPTION>EXHIBIT 99-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-right: 0; margin-left: 0"><B>Nektar Announces Topline
Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><I>NKTR-181 shows significantly less abuse
potential compared to oxycodone</I></B>&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><I>Analyst Conference Call and Webcast Today
at 5:45 a.m. PDT/8:45 a.m. EDT</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SAN FRANCISCO, July 18, 2017 /PRNewswire/ --&nbsp;Nektar
Therapeutics&nbsp; (NASDAQ: NKTR) announced positive topline results from an oral Human Abuse Potential (HAP) study of NKTR-181,
a first-in-class opioid analgesic.&nbsp; NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule
designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.<SUP>1</SUP>&nbsp;
NKTR-181 is the first analgesic opioid molecule to exhibit reduction in specific CNS-mediated side effects, like euphoria, through
the strategic alteration of brain-entry kinetics.&nbsp;&nbsp;The U.S. Food and Drug Administration (FDA) has granted the investigational
medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The NKTR-181 HAP study was designed to confirm
and assess the relative oral abuse potential of NKTR-181 at its maximum analgesic or therapeutic dose (400 mg) and at a supratherapeutic
dose (3 times to 12 times greater than its analgesic dose range of 100 mg to 400 mg) compared to common therapeutic doses of a
Schedule II opioid, oxycodone.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;Today's opioid abuse epidemic has created
a pressing need for a better pain medicine that does not possess the euphorigenic qualities of conventional opioids,&quot; said
Ivan Gergel, MD, Senior Vice President and Chief Medical Officer of Nektar.&nbsp; &quot;It is clear from our new study results
that NKTR-181 is highly differentiated in this respect from oxycodone, which is a choice drug of abuse.&nbsp; Further, and critically
important in the context of this public health emergency, NKTR-181's less rewarding properties and strong analgesia are inherent
to its novel molecular structure and independent of any abuse-deterrent formulation.&nbsp; Many patients do not receive adequate
pain relief because they fear taking conventional opioids, including abuse-deterrent formulations, because of their potential for
abuse and addiction.&nbsp; We believe NKTR-181 is a transformational pain medicine that should significantly advance the treatment
of chronic pain and could be a fundamental building block in the fight against prescription opioid abuse. We are committed to bringing
this new pain treatment to patients and physicians as quickly as possible.&quot;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Opioids act on specific receptors in the brain
to provide pain relief, but they also target the dopamine reward system in the brain to produce euphoria and other psychoactive
effects, which leads to addiction and abuse.<SUP>1&nbsp; </SUP>Brain imaging studies have shown that the faster a euphorigenic
drug enters and leaves the brain, the stronger are its reinforcing effects.<SUP>2</SUP> In 2014, nearly 2 million Americans either
abused or were dependent on prescription opioid pain relievers.<SUP>3&nbsp; </SUP>Opioid abuse is a growing epidemic in the U.S.,
with one in five Americans who say they have a family member who has been addicted to prescription painkillers.<SUP>4&nbsp; </SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;Getting very high, very fast, is a mark
of conventional high-risk, abused opioids,&quot; said Jack Henningfield, PhD, vice president at Pinney Associates and adjunct
professor at The Johns Hopkins University School of Medicine. &quot;NKTR-181 represents a meaningful advance in the treatment
of pain as the first opioid analgesic with inherent brain-entry kinetics that avoids this addictive quality of traditional opioids.
This prevents the rapid 'rush' that abusers seek during the critical period immediately after dosing. Importantly, these properties
of NKTR-181 are inherent to its molecular structure and are not changed through tampering or route of administration.&quot;&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In March 2017, NKTR-181 completed a Phase 3
efficacy trial (SUMMIT-07) in 610 patients with moderate to severe chronic low back pain who were new to opioid therapy (opioid-na&iuml;ve).&nbsp;
SUMMIT-07 evaluated four analgesic doses of NKTR-181 (100 mg, 200 mg, 300 mg and 400 mg).&nbsp; Patients in the trial achieved
an average pain score reduction of over 65% (from 6.73 at screening to 2.32 at randomization) during the dose titration period.&nbsp;&nbsp;
The primary efficacy endpoint of the study demonstrated significantly improved chronic back pain relief with NKTR-181 compared
to placebo (p=0.0019). Key secondary endpoints of the study also achieved high statistical significance. The study demonstrated
that NKTR-181 had a favorable safety profile and was well tolerated.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>HAP Study Design and Objectives</B><BR>
HAP studies are clinical studies that help assess the relative abuse potential of a medicine.&nbsp; The NKTR-181 HAP study was
a randomized, double-blind, placebo-controlled, six-sequence crossover study evaluating the relative oral abuse potential of NKTR-181
relative to the Schedule II opioid oxycodone in healthy non-dependent recreational drug users experienced in the oral abuse of
opioids who can identify drug effects that are relevant to abuse risk assessment.&nbsp; Subjects (n=54) were randomized to one
of six test sequences, in each of which they received a single dose of one of the six study drugs:</P>

<UL STYLE="list-style-type: disc">

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 400 mg (highest efficacious dose established in
the Phase 3 efficacy trial);</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 600 mg (a dose of 1.5 to 6 times greater than
the efficacious dose range established in the Phase 3 efficacy trial);</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 1200 mg (a supratherapeutic dose of 3 to 12 times
greater than the efficacious dose range of 100 mg to 400 mg established in the Phase 3 efficacy trial);</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">Moderate therapeutic dose of oxycodone at 40 mg</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">High therapeutic dose of oxycodone at 60 mg</LI>

</UL>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">There was a five-day washout period between
each treatment.&nbsp; NKTR-181 doses and its matching placebo were administered as oral tablets. Oxycodone HCl doses were administered
as over-encapsulated oral tablets.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The study evaluated effects that are predictive
of abuse potential with opioids for all doses in the study.&nbsp; The HAP trial was powered to detect a relative peak (Emax*) drug
liking score difference between oxycodone at 60 mg and NKTR-181 at 1,200 mg.&nbsp; Liking was based on a subject-reported 100-point
bipolar liking/disliking visual analog scale (VAS), which is a standard measure of abuse potential in HAP studies. Key secondary
endpoints were Area Under Effect for Drug Liking in the first 1, 2 and 3 hours after dosing as well as retrospective subject-reported
unipolar VAS ratings for Drug High and bipolar VAS ratings for Take Drug Again.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Topline Results</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Primary Endpoint of Drug Liking:</B></P>

<UL STYLE="list-style-type: disc">

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 400 mg had a significantly lower rating of peak
(Emax) liking compared to oxycodone 40 mg (62.0 vs. 76.6, p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 400 mg had a significantly lower rating of peak
(Emax) liking compared to oxycodone 60 mg (62.0 vs. 81.5, p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 600 mg had a significantly lower rating of peak
(Emax) liking compared to oxycodone 40 mg (67.9 vs. 76.6, p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 600 mg had a significantly lower rating of peak
(Emax) liking compared to oxycodone 60 mg (67.9 vs. 81.5, p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 1200 mg had a significantly lower rating of peak
(Emax) drug liking compared to oxycodone 60 mg (76.7 vs. 81.5, p=0.0071). This dose was not statistically different from oxycodone
40 mg.</LI>

</UL>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The peak liking score for NKTR-181 400 mg oral
tablet in this study confirmed the same peak liking score for NKTR-181 400 mg oral solution evaluated in the company's prior HAP
study (62.0 vs 62.3**).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Secondary Endpoint of Area Under Effect
(AUE) for Drug Liking Following Dosing (0-1 Hours, 0-2 Hours, 0-3 Hours):</B></P>

<UL STYLE="list-style-type: disc">

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 400 mg had significantly lower AUE for all timepoints
compared to both oxycodone 40 mg and 60 mg (p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 600 mg had significantly lower AUE for all timepoints
compared to both oxycodone 40 mg and 60 mg (p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 1200 mg had significantly lower AUE for all timepoints
compared to both oxycodone 40 mg and 60 mg. For AUE (0-1 Hours), p=0.0002 and p&lt;0.0001, respectively; for AUE 0-2 Hours, p=0.001
and p&lt;0.0001, respectively; for AUE 0-3 Hours, p=0.0396 and p=0.0003, respectively).&nbsp;&nbsp;</LI>

</UL>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Secondary Endpoint of Drug High:</B></P>

<UL STYLE="list-style-type: disc">

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 400 mg had significantly lower ratings of peak
(Emax) Drug High compared to both oxycodone 40 mg and 60 mg (p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 600 mg had significantly lower ratings of peak
(Emax) Drug High compared to both oxycodone 40 mg and 60 mg (p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 1200 mg had a significantly lower rating of peak
(Emax) Drug High compared to 60 mg oxycodone (p=0.0071).</LI>

</UL>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The peak Drug High score for NKTR-181 400 mg
oral tablet in this study confirmed the peak Drug High score in the first HAP trial, which evaluated 400 mg NKTR-181 as an oral
solution (21.3 vs 22.59**).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Secondary Endpoint of Take Drug Again:</B></P>

<UL STYLE="list-style-type: disc">

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 400 mg had significantly lower ratings of peak
(Emax) Take Drug Again compared to the 40 mg and 60 mg oxycodone (p&lt;0.0001).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 600 mg had significantly lower ratings of peak
(Emax) Take Drug Again compared to the 40 mg and 60 mg oxycodone (p=0.0004 and p&lt;0.0001, respectively).</LI>

<LI STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt">NKTR-181 1200 mg had a significantly lower rating of peak
Take Drug Again compared to 60 mg oxycodone (p=0.011).</LI>

</UL>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Full data from the NKTR-181 HAP study will
be presented at a future medical meeting.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Pain is one of the most common reasons people
seek medical treatment.<SUP>5</SUP> A study published in the American Pain Society's <I>The Journal of Pain</I> in October 2014
estimated that 19 percent of the U.S. population, or 39 million people, suffer from some type of persistent pain.<SUP>6&nbsp; </SUP>In
2015, there were nearly 22,000 deaths involving prescription opioids in the U.S.<SUP>7 </SUP>&nbsp;The health care utilization
consequences are also significant; for every one death from prescription opioids, it is estimated that there are 10 treatment admissions
for abuse, 32 emergency room visits for misuse or abuse, 130 people who are dependent, and 825 people who report non-medical use
of these drugs.<SUP>8</SUP></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Conference Call and Webcast Information</B><BR>
Nektar will host a conference call and webcast presentation today,&nbsp;July 18, 2017 at&nbsp;8:45 a.m. Eastern Daylight Time&nbsp;to
discuss the study results. The call can be accessed by dialing (877) 881-2183 (U.S.) or (970) 315-0453 (international), and entering
passcode 56389932. To access the live webcast, or the subsequent archived recording, visit the Investors section of the Nektar
website at&nbsp;www.nektar.com. The webcast will be available for replay on Nektar's website for two weeks following the call.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About NKTR-181 </B><BR>
NKTR-181 is the first long-acting, selective mu-opioid agonist designed to provide potent pain relief without the inherent high
levels of euphoria which lead to abuse and addiction with standard opioids.&nbsp; The novel molecular structure of NKTR-181 is
designed to have low permeability across the blood-brain barrier in order to slow its rate of entry into the brain and attenuate
the dopamine release that underlies euphoria.&nbsp; NKTR-181 is the first opioid molecule to exhibit reduction in specific CNS-mediated
side effects, like euphoria, through the strategic alteration of brain-entry kinetics.&nbsp;&nbsp;In addition, NKTR-181 is designed
with an inherent 12-hour elimination half-life to enable twice-daily dosing with continuous pain control.&nbsp; NKTR-181 is an
investigational medicine and has not been approved by the FDA or any other regulatory agencies.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Current and past strategies of abuse deterrence
to address the addictive qualities of standard opioids rely on formulations alone.&nbsp; However, all abuse-deterrent formulations
are pre-cursors to highly euphorigenic rapid-acting opioids, which can liberated through tampering.&nbsp; The National Survey on
Drug Use and Health (NSDUH) indicated that 16.0 million people in the U.S. reported using oxycodone products non-medically in their
lifetime in 2012.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Preclinical and clinical data show that the
inherent properties of NKTR-181 reduce its rate of entry into the brain compared to standard mu opioids, regardless of route of
administration.<SUP>9</SUP>&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Nektar Therapeutics </B><BR>
Nektar Therapeutics is a research-based biopharmaceutical company whose mission is to discover and develop innovative medicines
to address the unmet medical needs of patients. Our R&amp;D pipeline of new investigational medicines includes treatments for cancer,
auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design
of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville,
Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found
online at http://www.nektar.com.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Cautionary Note Regarding Forward-Looking
Statements<BR> <I>This press release contains forward-looking statements which can be identified by words such as: &quot;plan,&quot;
&quot;expect,&quot; &quot;may,&quot; &quot;will,&quot; &quot;believe,&quot; &quot;can,&quot; &quot;should,&quot; &quot;could&quot;
and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding
the potential therapeutic benefit of NKTR-181 for treating patients with pain, the potential importance of NKTR-181's development
in the area of new pain medicines, the risks of opioid abuse resulting from use of NKTR-181, as well as from new and existing
pain medicines, future development plans for NKTR-181 (including, but not limited to, future clinical development plans and future
regulatory filings seeking regulatory approval for NKTR-181), the potential timeframe for commercial availability of NKTR-181,
and certain other statements regarding the prospects and potential of NKTR-181 specifically, and Nektar's business and technology
platform generally.&nbsp; Forward-looking statements are neither historical facts nor assurances of future performance. Instead,
they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate
to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and
many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking
statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our
actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) challenges
and uncertainties inherent in pharmaceutical research and development, including the uncertainty of future clinical and regulatory
success, where the risk of failure remains high and failure can unexpectedly occur at any stage prior to regulatory approval due
to lack of sufficient efficacy, safety considerations or other factors; (ii) the regulatory pathway to review and approve NKTR-181
for use in patients, even with a Fast Track designation by the FDA, is subject to substantial uncertainty; (iii) regulations concerning
and controlling the access to opioid-based pharmaceuticals are strict and there is no guarantee which scheduling category will
apply to NKTR-181 if regulatory approval is achieved; (iv) the partnering process for NKTR-181 is at an early stage and there
is therefore substantial uncertainty as to the timing and terms of a potential partnership, or the success of our partnering efforts;
(v) drug manufacturing challenges which can delay or render unavailable sufficient supplies of NKTR-181; (vi) changing standards
of care and new regulations (including, but not limited to, standards and regulations related to health care cost containment)
can affect the use NKTR-181 and commercial success following a regulatory approval; (vii) Nektar's patent applications for NKTR-181
may not issue in one or more jurisdictions, patents that have issued may not be enforceable, or additional intellectual property
licenses from third parties may be required in the future; (viii) the outcome of any existing or future intellectual property
or other litigation related to Nektar's proprietary product candidates, including, without limitation, NKTR-181, is unpredictable
and could have a material adverse effect on our business; and (ix) certain other important risks and uncertainties set forth in
Nektar's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the Securities and Exchange Commission
on May 10, 2017. Any forward-looking statement made by us in this press release is based only on information currently available
to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement,
whether written or oral, that may be made from</I> time to time, whether as a result of new information, future developments or
otherwise.&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;<B>Contact: </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">For Investors:&nbsp;<BR>
Jennifer Ruddock of Nektar Therapeutics<BR>
415-482-5585</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Jodi Sievers of Nektar Therapeutics<BR>
415-482-5593</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">For Media:<BR>
Dan Budwick&nbsp;<BR>
1AB Media&nbsp;<BR>
973.271.6085</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><I>* Emax equal to Maximum Effect (at all timepoints)<BR>
** Webster et al.; Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.&nbsp;Pain Med&nbsp;2017
pnw344. doi: 10.1093/pm/pnw344</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">1. Melnikova, I, Pain Market, Nature Reviews
Drug Discovery, Volume 9, 589-90 (August 2010).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">2. Volkow, N., et al., Addiction: Beyond dopamine
reward circuitry; PNAS, Volume 108(37), 15037-15042 (September 2011)</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">3. Substance Abuse and Mental Health Services
Administration, National Survey on Drug Use and Health, 2014.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">4. The Washington Post/Kaiser Family Foundation
Survey of Long-Term Prescription Painkiller Users and Their Household Members:&nbsp;http://kff.org/other/report/the-washington-post-kaiser-family-foundation-survey-of-long-term-prescription-painkiller-users-and-their-household-members.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">5. 2011 National Academy of Sciences. Relieving
Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research, 2010 Decision Resources, and Harstall,
C. How prevalent is chronic pain? Pain Clinical Updates X, 1-4 (2003).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">6 http://americanpainsociety.org/about-us/press-room/persistent-pain-incidence-news-release.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">7. CDC. Wide-ranging online data for epidemiologic
research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at&nbsp;http://wonder.cdc.gov.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">8. Centers for Disease Control and Prevention.
Policy Impact: Prescription Painkiller Overdoses. 2011 https://www.cdc.gov/drugoverdose/pdf/policyimpact-prescriptionpainkillerod-a.pdf#page=5</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">9. 2010&nbsp;Society of Neuroscience&nbsp;Annual
Meeting (Nov 13-17, #HHH11).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
